Clinical trial
A Phase Ib/II Study of SHR-A1811 Combinations in Patients With Advanced/Metastatic HER2 Expression Gastric /Gastroesophageal Junction Adenocarcinoma
NCT05671822 is registered in ClinicalTrials.gov with Suzhou Suncadia Biopharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib/II Study of SHR-A1811 Combinations in Patients With Advanced/Metastatic HER2 Expression Gastric /Gastroesophageal Junction Adenocarcinoma
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- March 14, 2023
- Completion date
- December 31, 2027
- Enrollment
- 258 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
her2 expression gastric cancer/gastroesophageal junction adenocarcinoma